ArticleJournal of translational medicine2026
Cathepsin H as a causal risk factor and therapeutic target in proliferative diabetic retinopathy.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cathepsins as Core Players in Obesity Pathogenesis: Emerging Therapeutic Targets.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCathepsins, key lysosomal proteases, have been linked to diabetic retinopathy (DR) pathogenesis, but their causal role and therapeutic potential remain unclear.
methodsWe used bidirectional Mendelian randomization (MR) to explore causal relationships between cathepsins and DR stages, with validation by multivariable MR, Bayesian weighted MR, and colocalization analysis. Single-cell RNA sequencing (scRNA-seq) characterized cellular expression of relevant cathepsins in DR patients and mice. Candidate inhibitors were screened via the Proteomics Drug Atlas, followed by molecular docking and dynamics simulating their binding stability. Cellular experiments (CCK-8, scratch assay, LysoTracker staining) were performed to evaluate drug efficacy.
resultsCathepsin H (CtsH) showed a causal association with proliferative DR (PDR) (IVW: p = 0.01, OR = 1.059), which was confirmed by multivariable and Bayesian MR. Colocalization identified shared genetic variants between CtsH and PDR (PP.H4 = 99.99%). ScRNA-seq revealed CtsH upregulation in monocytes of DR patients’ peripheral blood mononuclear cells and in retinal macroglia/endothelial cells of DR mice. Molecular docking demonstrated stable binding of SSR 69071 and PF429242 to CtsH (binding energies: −7.7 and −6.6 kcal/mol), with 100-ns dynamics confirming complex stability. In vitro, both compounds inhibited endothelial migration and wound healing in a time- and dose-dependent manner at safe concentrations (SSR 69071 ≤ 1 μM; PF429242 ≤ 10 μM), while PF429242 additionally increased lysosomal area.
conclusionsElevated CtsH is an independent causal risk factor for PDR. The SSR 69071 and PF429242 exhibit promising inhibitory effects, supporting CtsH as both a biomarker and therapeutic target for PDR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.